About us

Creating a world where people no longer suffer from neuropsychiatric illness


Our Background

Transcend Therapeutics, founded in 2021, is a clinical-stage, neuroscience-focused company developing rapid-acting treatments for neuropsychiatric diseases. Our mission is to develop new drugs for the millions of people for whom current psychiatric medicines have not worked.

We are developing TSND-201 (methylone) as a rapid-acting and durable treatment for Post-Traumatic Stress Disorder (PTSD), Major Depressive Disorder (MDD), and other Central Nervous System (CNS) indications.

As a Public Benefit Corporation, we have pledged 10% of founding shares toward nonprofits focused on scientific research and access.


Our Leadership Team

Our leadership team has made pivotal contributions to 13 FDA approvals and $7B in M&A and public company value.

Our Lead Investors